Bromopyruvic acid (3-BP)

Catalog No.S5426 Batch:S542602

Print

Technical Data

Formula

C3H3BrO3
Molecular Weight 166.96 CAS No. 1113-59-3
Solubility (25°C)* In vitro DMSO 33 mg/mL (197.65 mM)
Water 33 mg/mL (197.65 mM)
Ethanol 33 mg/mL (197.65 mM)
In vivo (Add solvents to the product individually and in order)
Clear solution
5% DMSO 95% Corn oil
1.65mg/ml Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.65mg/ml Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Bromopyruvic acid (3-BP) is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
In vitro

Bromopyruvic acid, a glycolysis inhibitor, maintains haploidy to a certain extent in both OdG and EG1 haESCs, with no effect on the proliferation or pluripotency of the haESCs.[2]
In vivo

Bromopyruvic acid reduces the growth of RKO cells with CD36 knockdown at a significantly slower rate in xenograft model.[3]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    Mouse haESC lines AGH-OG-3 and AGH-EG-1

  • Concentrations

    12.5 μg/mL

  • Incubation Time

    12 days

  • Method

    Mouse haESC lines AGH-OG-3 and AGH-EG-1 were cultured in M2iL mediums, which containing knockout DMEM, 15% fetal bovine serum, 1% GlutaMAX, 1% nonessential amino acids, 100 μM β-mercaptoethanol, 100 U Leukemia inhibitory factor, 3 μM CHIR99021, and 1 μM PD0325901. The cells are cultured at 37 ℃ with 5% CO2 in a humidified environment. 1,25-(OH)2D3 and 3-BrPA are used at a final concentration of 12.5 μg/mL and 5μM, respectively.
Animal Study:

[3]
  • Animal Models

    4-week-old nude mice injected with RKO cells

  • Dosages

    5 mg/kg/day

  • Administration

    i.p.

Selleck's Bromopyruvic acid (3-BP) has been cited by 15 publications

GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism [ iScience, 2024, 27(3):109246] PubMed: 38439974
Hexokinase 2 nonmetabolic function-mediated phosphorylation of IκBα enhances pancreatic ductal adenocarcinoma progression [ Cancer Sci, 2024, 10.1111/cas.16204] PubMed: 38801832
METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53-wild-type cells [ EMBO Rep, 2023, e56325.] PubMed: 36794620
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis [ Cancer Gene Ther, 2023, 10.1038/s41417-023-00648-5] PubMed: 37558749
ASPP2 suppresses tumour growth and stemness characteristics in HCC by inhibiting Warburg effect via WNT/β-catenin/HK2 axis [ J Cell Mol Med, 2023, 27(5):659-671] PubMed: 36752127
Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance [ Nat Metab, 2022, 4(10):1287-1305] PubMed: 36203054
Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC [ Hepatology, 2022, 75(6):1386-1401] PubMed: 34580888
Inhibition of abnormally activated HIF-1α-GLUT1/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives [ Eur J Pharmacol, 2022, S0014-2999(22)00105-4] PubMed: 35189090
Viral growth factor- and STAT3 signaling-dependent elevation of the TCA cycle intermediate levels during vaccinia virus infection [ PLoS Pathog, 2021, 17(2):e1009303] PubMed: 33529218
Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis [ Mol Oncol, 2021, 10.1002/1878-0261.12917] PubMed: 33528867

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.